Company news
Telix Pharmaceuticals Limited (ASX:TLX) news
Telix Pharmaceuticals Limited news releases on 6ix. Latest, Feb 20, 2026: Telix to Participate in Oppenheimer and TD Cowen Conferences
Press releases — page 2
Telix to Participate in Oppenheimer and TD Cowen Conferences
February 20, 2026
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
February 19, 2026
2025 Full Year Results Presentation
February 19, 2026
Appendix 4E and 2025 Annual Report
February 19, 2026
2025 Full Year Results Announcement
February 19, 2026
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
February 17, 2026
Telix Submits EU MAA for TLX101-Px Brain Cancer Imaging
February 17, 2026
Telix Full Year Results 2025 Investor Webcast Notification
February 3, 2026
First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients
January 28, 2026
Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging
January 19, 2026
Telix Achieves FY25 Guidance - US$804M, Q4 Growth
January 20, 2026
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
January 20, 2026
Chinese NMPA Accepts New Drug Application for Illuccix
January 19, 2026
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
January 16, 2026
Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
January 8, 2026
Precision Medicine Portfolio Update
December 21, 2025
ProstACT Global Study Status
December 17, 2025
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
December 10, 2025
1st Patient Dosed in ProstACT Global Randomized Tx Expansion
December 7, 2025
Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held
November 21, 2025
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
November 19, 2025
OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
November 11, 2025
Telix to Participate in UBS and Jefferies Global Healthcare Conferences
November 5, 2025
Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain
October 22, 2025
TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging
October 23, 2025
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
October 14, 2025
Telix Announces Record-Breaking Presence at EANM 2025
September 29, 2025
CMS Grants Transitional Pass-Through Status for Gozellix
September 22, 2025
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
September 9, 2025
Telix and FDA Agree Resubmission Pathway for Pixclara NDA
September 8, 2025
Telix Provides Regulatory Update on TLX250-CDx
August 27, 2025
Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference
August 26, 2025
Telix H1 2025 Results Announcement
August 20, 2025
Telix H1 2025 Results Presentation
August 20, 2025
Telix H1 2025 Appendix 4D and Interim Report
August 20, 2025
Historical Financials in USD and H12025 OPEX (Unaudited)
August 4, 2025
Telix H1 2025 Results: Investor Webcast Notification
July 29, 2025
Telix Reports US$204M Q2 Revenue, Up 63% YOY
July 22, 2025
Gozellix Receives Permanent HCPCS Code
July 9, 2025
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
June 23, 2025
Telix Precision Medicine Announces AlFluor Radiochemistry Platform
June 20, 2025
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
June 19, 2025
Telix Investor Day Presentation
June 11, 2025
Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan
June 3, 2025
Telix to Host Investor Day in New York City on June 11, 2025
May 22, 2025
Telix at ANZSNM Annual Scientific Meeting 2025
May 19, 2025
Illuccix China Phase 3 Study Completes Enrolment
May 12, 2025
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
May 7, 2025
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
April 28, 2025
Telix Provides Regulatory Update on TLX101-CDx
April 27, 2025